跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
查看斯高帕斯 (Scopus) 概要
吳 貞宜
教授
醫學系皮膚學科
h-index
h10-index
h5-index
1743
引文
25
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
727
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
217
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2010
2025
每年研究成果
概覽
指紋
網路
研究成果
(91)
類似的個人檔案
(6)
指紋
查看啟用 Chen-Yi Wu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Air Quality Index
10%
All-cause Mortality
12%
Atopic Dermatitis
20%
Body Mass Index
14%
Bullous Pemphigoid
43%
Cancer Mortality
9%
Cardiovascular Mortality
15%
Cigarette Smoking
10%
Collaborative Coefficient
7%
Community-dwelling Older Adults
10%
Comorbidity
12%
Confidence Interval
55%
COVID-19 Vaccination
7%
Gemcitabine
7%
Hazard Ratio
49%
Hepatocellular Carcinoma
7%
Hepatocellular Carcinoma Patients
7%
Herpes Zoster
16%
Hypertension
8%
Incidence Rate
7%
Interprofessional Collaboration
7%
Interprofessional Teams
7%
Low Risk
7%
Mortality in Elderly
7%
Mortality Risk
12%
National Cohort Study
74%
National Health Insurance Research Database (NHIRD)
9%
Nested Case-control Study
7%
Non-melanoma Skin Cancer
7%
Nucleos(t)ide Analogues
7%
Obesity
10%
Odds Ratio
12%
Older Adults
8%
Pancreatic Cancer
7%
Population-based Cohort Study
54%
Population-based Study
8%
Postherpetic Neuralgia
7%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
7%
Psoriasis
33%
Retrospective Cohort Study
12%
Risk Factors
17%
Risk Reduction
7%
Rosaceae
14%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
7%
Taiwan
84%
Taiwan National Health Insurance Research Database
8%
Team Effectiveness
7%
Type 1 Diabetes Mellitus (T1DM)
7%
Type 2 Diabetic Patients
8%
Vitiligo
8%
Medicine and Dentistry
Alcohol Consumption
5%
All Cause Mortality
5%
Atopic Dermatitis
11%
Autoimmune Disease
5%
Bullous Pemphigoid
32%
Cancer
8%
Cancer Mortality
5%
Case-Control Study
7%
Cigarette Smoking
10%
Cohort Analysis
100%
Comorbidity
8%
COVID-19 Vaccination
7%
Diabetes Mellitus
6%
Disseminated Herpes Zoster
14%
Geriatrics
7%
Hazard Ratio
35%
Health Care
7%
Hepatitis B
7%
Hepatitis C
5%
Malignant Neoplasm
14%
Non Melanoma Skin Cancer
7%
Odds Ratio
8%
Patient with Type 2 Diabetes
8%
Postherpetic Neuralgia
7%
Proportional Hazards Model
6%
Proprotein Convertase 9
7%
Psoriasis
29%
Retrospective Cohort Study
12%
Rhinophyma
14%
Smoking
5%
Symptomatic Treatment
7%
Vitiligo
7%
